Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Accured Expenses (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Change in Accured Expenses data on record, last reported at -$42.6 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 2119.13% year-over-year to -$42.6 million; the TTM value through Dec 2025 reached -$4.6 million, down 107.17%, while the annual FY2025 figure was -$4.6 million, 107.17% down from the prior year.
  • Change in Accured Expenses reached -$42.6 million in Q4 2025 per AMPH's latest filing, down from $25.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $25.3 million in Q3 2025 and bottomed at -$42.6 million in Q4 2025.
  • Average Change in Accured Expenses over 5 years is $3.8 million, with a median of $3.4 million recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: soared 2803.38% in 2023, then plummeted 2119.13% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$1.1 million in 2021, then tumbled by 1162.27% to -$13.6 million in 2022, then soared by 75.06% to -$3.4 million in 2023, then soared by 162.34% to $2.1 million in 2024, then tumbled by 2119.13% to -$42.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$42.6 million in Q4 2025, $25.3 million in Q3 2025, and -$4.9 million in Q2 2025.